Pharmacological management of metabolic syndrome and its lipid complications

DARU, Journal of Pharmaceutical Sciences

Volumn 18, Issue 3, 2010, Pages 146-154

  Binesh Marvasti, T ^a   Adeli, Kh ^a  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

HDL cholesterol; LDL Cholesterol; Triglycerides (TG); Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; EZETIMIBE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MEVINOLIN; PLACEBO; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HOMEOSTASIS; HUMAN; HYDROLYSIS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

EID: 78149455110     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
2. Reaven G. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu.Rev. Nutr. 2005; 25: 391-406.
3. Meigs J.B., Mittleman M.A., Nathan D.M., Tofler G.H., Singer D.E. Murphy-Sheehy PM. Hyperinsulinemia, hyperglycemia. and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228.
4. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. Ann.Clin.Biochem. 2007; 44: 232-263.
5. Hadaegh F, Shafiee G, Ghasemi A, Sarbakhsh P, Azizi F. Impact of metabolic syndrome, diabetes and prediabetes on cardiovascular events: Tehran lipid and glucose study. Diabetes Res.Clin.Pract. 2010; 87: 342-347.
6. Fonseca V. The metabolic syndrome, hyperlipidemia, and insulin resistance. Clin.Cornerstone 2005; 7: 61-72.
7. Bosevski M, Pemovska G, Bosevska G, Georgievska L. Clinical Role of Estimation Metabolic Syndrome's Components in Type 2 Diabetes Population with Symptomatic Coronary Artery Disease. Med Arh. 2010; 64: 144-6.
8. Lewis G.F., Uffelman K.D., Szeto L.W., Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J.Clin.Invest. 1995; 95: 158-166.
9. Mohammadi A, Macri J, Newton R, Romain T, Dulay D, Adeli K. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler.Thromb.Vasc.Biol. 1998; 18: 783-793.
10. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J.Lipid Res. 1990; 31: 567-582.
11. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Davignon J, Isaacsohn J.L., Weiss S.R. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133.
12. Ginsberg H. REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J.Clin.Endocrinol.Metab. 2006; 91: 383-392.
13. Mangaloglu L, Cheung R, Van Iderstine S, Taghibiglou C, Pontrelli L, Adeli K. Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity. Metabolism, clinical and experimental 2002; 51: 409-418.
14. Pola P, Kumar R, Reddy A.P., Rajagopal G, Harinaray A, Suresh V. Efficacy of Low Dose Atorvastatin in Diabetic Dyslipidaemia. J Indian Med Assoc. 2009 Nov; 107: 807-9.
15. Bonn V, Cheung R, Chen B, Taghibiglou C, Van Iderstine S, Adeli K. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 2002; 163: 59-68.
16. Brunzell J.D., Hokanson J.E. Low-density and high-density lipoprotein subspecies and risk for premature coronary artery disease. Am.J.Med. 1999; 107: 16S-18S.
17. Tribble D.L., Krauss R.M. HDL and coronary artery disease. Adv.Intern.Med. 1993; 38: 1-29.
18. Conde K, Vergara-Jimenez M, Krause B.R., Newton R.S., Fernandez M.L. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J.Lipid Res. 1996; 37: 2372-2382.
19. Kendrach M, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann.Pharmacother. 2004; 38: 1286-1292.
20. Istvan E.S. Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures. Curr.Opin.Struct.Biol. 2001; 11: 746-751.
21. Naples M, Federico L, Xu E, Nelken J, Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis 2008; 198: 94-103.
22. McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis.Supplements 2003; 4: 9-14.
23. Park J.S., Kim Y.J., Choi J.Y., Kin Y.N., Hong T.J., Kim D.S., Ki. K.Y. Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Pateints with Metabolic Syndrome and Hypercholesterolemia. Korean Intern Med. 2010 Mar; 25: 27-35. Epub 2010 Feb 26.
24. Bass A. Hinderliter A. Lee C. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann.Pharmacother. 2009; 43: 2021-2030.
25. Bays H. Neff D. Tomassini J. Tershakovec A. Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 2008; 6: 447-470.
26. Grundy S. Cleeman J. Merz C.N.B., Brewer H.B., Clark L. Hunninghake D. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J.Am.Coll.Cardiol. 2004; 44: 720-732.
27. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23 Suppl 1):III39- III43.
28. Landmesser U. Bahlmann F. Mueller M. Spiekermann S. Kirchhoff N. Schulz S. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-2363.
29. Burnett J.R., Wilcox L.J., Telford D.E., Kleinstiver S.J., Barrett P.H., Newton R.S. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 1999; 140: 5293-5302.
30. Olijhoek J, Hajer G, van der Graaf Y, Dallinga-Thie G, Visseren F.L.J. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J.Cardiovasc.Pharmacol. 2008; 52: 145-150.
31. Zinman B, Harris S.B, Neuman J, Gerstein H.C., Retnakaran R.R., Raboud J. Qi Y. Hanley AJ.Low-Dose Combination therapy with Rosiglitazone and Metformain to Prevent Type 2 Diabetes Mellitus (CANOE trial): A Double-Blind Randomized Controlled Study. Lancet. 2010; 376: 103-11.
32. Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis 1998; 137: 341-349.
33. Haffner S.M., Foster D.M., Kushwaha R.S., Hazzard W.R. Retarded chylomicron apolipoprotein-B catabolism in type 2 (non-insulin-dependent) diabetic subjects with lipaemia. Diabetologia 1984; 26: 349-354.
34. Bar-on H. Levy E. Oschry Y. Ziv E. Shafrir E. Removal defect of very-low-density lipoproteins from diabetic rats. Biochim.Biophys.Acta 1984; 793: 115-118.
35. Carpentier A, Taghibiglou C, Leung N, Szeto L, Van Iderstine S, Uffelman K. Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster. The Journal of biological chemistry 2002; 277: 28795-28802.
36. Lewis G, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed Syrian golden hamster. Endocrinology 2005; 146: 247-255.
37. Bailey C.J., Turner R.C. Metformin. New England Journal of Medicine, The 1996; 334: 574-579.
38. Krentz A, Patel M, Bailey C. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68: 2131-2162.
39. Scheen A.J. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes metabolism 2007; 33: 3-12.
40. Ahrn B. Gut peptides and type 2 diabetes mellitus treatment. Current Diabetes Reports 2003; 3: 365-372.
41. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology 2001; 142: 521-527.
42. Meier J, Nauck M. Incretins and the development of type 2 diabetes. Current Diabetes Reports 2006; 6: 194-201.
43. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253-260.
44. Kendall D, Kim D, Maggs D. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes technology therapeutics 2006; 8: 385-396.
45. Baggio L, Drucker D. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu.Rev.Med. 2006; 57: 265-281.
46. Iltz J, Baker D. Setter S. Campbell RK. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin.Ther. 2006; 28: 652-665.
47. Barnett A. Exenatide. Expert Opin.Pharmacother. 2007; 8: 2593-2608.
48. Klonoff D, Buse J, Nielsen L, Guan X, Bowlus C, Holcombe J. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr.Med.Res.Opin. 2008; 24: 275-286.
49. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int.J.Clin.Pract. 2006; 60: 1454-1470.